Novo Nordisk, maker of the weight-loss drug Wegovy, said it would limit supply of starter doses as demand outpaces the company’s manufacturing capacity. CNN values your feedback 1.

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

The study found that GLP-1 medications, in particular, showed significant weight regain after treatment discontinuation.

Ozempic and Wegovy share the common side effects of nausea and appetite loss, but there is one lesser-known risk factor that isn’t mentioned nearly as often. The two semaglutide-containing ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

GoodRx reports on identifying real Wegovy pens, which come in five colors and lack dose selectors. Counterfeits pose health ...

The diabetes drugs Ozempic and Wegovy have been linked to an increased risk of sudden vision loss and blindness due to a rare ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

Novo Nordisk announced it is cutting ties with telehealth giant Hims & Hers Health, pulling its blockbuster drug Wegovy from ...

India's anti-obesity drug market is valued at Rs 3,000-3,500 crore and is projected to grow nearly eightfold to Rs 25,000 ...